Overview

Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
AB-10-8003 is a randomized, multi-center phase II study to evaluate the efficacy and safety of AHB-137 in subjects with HBeAg-negative CHB under stable NA treatment.
Phase:
PHASE2
Details
Lead Sponsor:
Ausper Biopharma Co., Ltd.